Our Partners
We work collaboratively with MS care providers, patient advocacy organizations, healthcare institutions and pharmaceutical companies to serve our vibrant community of Black women living with multiple sclerosis. Together, we’re changing lives!
At EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany in the U.S., we aspire to create, improve and prolong life for people living with difficult-to-treat conditions like infertility, multiple sclerosis and cancer. We have a deep legacy of impacting lives and we’re fueled for the future, driven by patient needs. We’re imagining the future of healthcare by turning science into solutions across a wide range of cancers, multiple sclerosis, and other immunologic disorders.
Neuroscience is a major focus of research and development at Genentech. Our goal is to pursue groundbreaking science to develop new treatments that help improve the lives of people with chronic and potentially devastating diseases.
Genentech is investigating more than a dozen medicines for neurological disorders, including multiple sclerosis (MS), spinal muscular atrophy (SMA), neuromyelitis optica spectrum disorder (NMOSD), Alzheimer’s, Huntington’s, Parkinson’s, acute ischemic stroke, Duchenne muscular dystrophy and Angelman syndrome. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neuroscience today.
Novartis’ purpose is to reimagine medicine to improve and extend people’s lives. We use innovative science and technology to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. We also aim to reward those who invest their money, time and ideas in our company.
We are Sanofi, an innovative global healthcare company. We chase the miracles of science to improve people’s lives. Since 2012, we’ve been working to improve the lives of people with serious neuro-degenerative diseases. Sanofi is developing new medicines built on patient insights and outstanding science to help the millions of people living with neurological disorders. We engage with the patient advocacy community to listen to their perspectives, understand what matters most to patients, and champion these patient-centric insights internally and externally.
We’re taking on the complex challenges of neurological diseases, advancing scientific understanding and developing treatments to address long-unmet needs. For more than 18 years, we’ve worked relentlessly to deliver disease-modifying therapies for MS with distinct indications and mechanisms of action. The goal is to design best-in-class medicines that slow or halt neurodegeneration, control neuroinflammation, and protect or even repair the nervous system.